Aethlon Medical, Inc. is a San Diego-based medical therapeutic company developing the Hemopurifier®, a clinical-stage extracorporeal immunotherapeutic device designed to remove enveloped viruses and harmful extracellular vesicles (EVs) from biological fluids using a proprietary lectin-based mechanism. The company is targeting applications in cancer, life-threatening viral infections, and organ transplantation—areas where clinical adoption depends on human study outcomes and regulatory clearance. The FDA has designated the Hemopurifier as a Breakthrough Device for two independent indications, positioning the program for potentially accelerated regulatory interaction but not reducing the need for robust clinical evidence. Aethlon remains pre-commercial and its near-term business model is centered on advancing clinical trials, securing manufacturing readiness, and building the reimbursement and clinical-use case required for hospital adoption.
3.85
3.85
| % | |
|---|---|
| Hemopurifier device program | 80% Core clinical-stage extracorporeal device and single-use components intended to remove viruses and EVs. |
| Clinical development and regulatory activities | 15% Human studies, preclinical research, and FDA/foreign regulatory work to support future clearance. |
| Intellectual property and platform extensions | 5% Patents, trademarks, and potential new indications leveraging the lectin-based mechanism. |
As a clinical-stage company, Aethlon’s near-term “customers” are primarily clinical trial sites and investigators that...
Would purchase Hemopurifier treatments/devices if cleared, driven by clinical outcomes and reimbursement feasibility.
Potential users where EV removal could support treatment strategies tied to immune suppression and metastasis.
Potential users for life-threatening viral infections where rapid viral/EV reduction could be clinically meaningful.
Potential users in organ transplantation settings as an adjunct immunotherapeutic approach.
Aethlon Medical is headquartered in San Diego, California and is incorporated in Nevada, with U.S...
The company’s strategy centers on advancing the Hemopurifier through clinical development to generate human data that...
Human data is required to gain regulatory clearance and clinician support for a clinical-stage device.
Regulatory progress is gating for commercialization and partnering/manufacturing scale-up decisions.
Commercial viability requires scalable production, qualified materials, and compliance with good manufacturing practices.
Aethlon faces development-stage risk: the Hemopurifier is not yet commercialized and its prospects depend on successful...
The company expects to continue incurring losses and requires financing to sustain operations and trials, which may dilute shareholders.
Delays/interruptions by third-party suppliers or delays qualifying materials can prevent or delay Hemopurifier manufacturing.
Failure to comply with extensive regulations or inadequate funding/staffing at FDA/foreign agencies could delay or prevent commercialization.
Hospitals rely on third-party payors; CMS coverage requires demonstrating treatment is reasonable and necessary and the process is lengthy and expensive.
New scientific developments or better/economical competing products could render the Hemopurifier unmarketable; competitors include ExThera blood filters.
AEMD · Surgical & Medical Instruments & Apparatus
AGL · Services-Misc Health & Allied Services, NEC
AEON · Pharmaceutical Preparations
ESMC · Electromedical & Electrotherapeutic Apparatus
DXCM · Surgical & Medical Instruments & Apparatus
DexCom is a U.S.
BDX · Surgical & Medical Instruments & Apparatus
Becton, Dickinson and Company (BD) is a U.S.-based medical technology company with roots dating back to 1897 and incorporation in 1906.
: 11/08/2026